Image
Recommendation
Assessment of markers (ER, PR and HER2) #1
Request simultaneously the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) status of all core biopsies of invasive breast cancers, at the time of initial histopathological diagnosis.
Request the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) status of all invasive breast cancers simultaneously at the time of initial histopathological diagnosis
How this guidance was developed
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Request’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no changes to the meaning or tone of the source recommendation.
Assessment of markers (ER, PR and HER2) #1
Recommendation
Request simultaneously the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) status of all core biopsies of invasive breast cancers, at the time of initial histopathological diagnosis.
Principles in action
Safe and quality care
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Request’) indicative of a strong recommendation (using GRADE methods) by the source guideline authors. The source recommendation was accepted with minor stylistic changes, but with no changes to the meaning or tone of the source recommendation.